The aim of this retrospective study was to assess the rate of full donor chimerism (F‐DC) in
patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two …

We investigated risk factors for the development of mixed chimerism in 131 patients who
underwent transplantation for myelofibrosis and determined the impact of lymphoid (CD3+) …

Objectives We evaluated the safety and outcome of allo‐HSCT s in myelofibrosis (MF).
Methods A total of 27 patients with primary (n= 20) or secondary (n= 7) MF, aged 51 (21–63) …

A total of 21 patients with myelofibrosis with myeloid metaplasia (MMM), with a median age
of 54 years (range, 27-68 years), were prepared with a reduced-intensity conditioning (RIC) …

Allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative
treatment for myelofibrosis (MF). 1, 2 The 5-year overall survival (OS) rates in MF patients …

Hematopoietic cell transplantation (HCT) is a curative approach for myelofibrosis patients,
but relapse is a major cause of treatment failure. We investigated the effect of donor …

We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation
(HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant …

The aim of this study is to compare clinical outcomes of patients who underwent allogeneic
stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) …

Allogeneic transplantation is the only potentially curative strategy for myelofibrosis, even in
the era of new drugs that so far only mitigate symptoms. The choice to proceed to allogeneic …

We report the results from a multicenter retrospective study of 69 adult patients who
underwent haploidentical blood or marrow transplantation (haplo-BMT) with post …